Hoosier Cancer Research Network investigators highlighted an HCRN melanoma study as a poster presentation during the Society for Melanoma Research 16th International Congress, Nov. 20-23, 2019, in Salt Lake City, Utah.

The authors, led by sponsor-investigator Suthee Rapisuwon, MD (pictured left), and co-investigator Michael B. Atkins, MD, both of Georgetown University Lombardi Comprehensive Cancer Center, presented the MEL17-309 study, in a poster titled “Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.” (See abstract.)

The primary endpoint of the MEL17-309 study is 3-year relapse-free survival rate. Secondary endpoints are median relapse-free survival, median overall survival, 3-year overall survival rate, and safety.

Authors include Suthee Rapisuwon¹, Sapna P. Patel², Richard D. Carvajal³, Leonel F. Hernandez-Aya⁴, Katy Tsai⁵, Sunandana Chandra⁶, Ming T. Tan¹, Adil Daud⁵, Jeffrey A. Sosman⁶, and Michael B. Atkins¹. (¹Oncology, Georgetown University-Lombardi Comprehensive Cancer Center, Washington, DC; ²University of Texas-MD Anderson Cancer Center, Houston, TX; ³Columbia University-The Herbert Irving Comprehensive Cancer Center, New York, NY; ⁴Washington University School of Medicine, St. Louis, MO; ⁵Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; ⁶Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL)

Congratulations to all study authors and teams participating in the MEL17-309 study!

 
About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 210 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 8,500 subjects have participated in Hoosier Cancer Research Network clinical trials.